罕见血友病因素市场：现况分析与预测（2023-2030）

Rare Hemophilia Factors Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年12月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于老年人口的增加，预计罕见血友病因子市场在预测期内将以 5.2% 的复合年增长率增长。罕见出血性疾病包括一组比血友病不太常见的遗传性凝血疾病。这些疾病通常发生在老年人身上。根据美国人口普查局的数据，到 2050 年，全球 65 岁及以上人口预计将达到 16 亿，是 2018 年这一数字的两倍多。同样，世界卫生组织 (WHO) 估计，到 2050 年，60 岁及以上的人口数量将从 2017 年的 9.62 亿增加近两倍，达到 21 亿。这些统计数据表明，全球老年人口正在显着增加。

市场依类型分为因子 I、因子 II、因子 VII、因子 X、因子 XIII 等。由于这种缺陷的发生率很高，到 2022 年，因子 VII 细分市场将占据大部分市场份额。根据美国国家出血性疾病基金会的数据，凝血因子 VII 缺乏症的发生率为每 30 万至 50 万人中 1 人，即每百万人 2.5 人。凝血因子 VII 是凝血级联中最重要的凝血蛋白□之一，关键参与启动蛋白水解事件，最终导致凝血□生成、纤维蛋白沉积和血小板活化。凝血因子 VII 缺乏通常是体染色体隐性遗传，男性和女性均等遗传。因此，VII因子细分市场将在2022年占据主要市场份额。

依治疗方式，市场分为浓缩因子 VII 製剂、新鲜冷冻血浆、冷沉淀溶液等。由于药品需求增加、对药品安全选择的需求、策略联盟和合作研究以及创新产品的推出进一步推动了对智慧产品的需求，预计新鲜冰冻血浆细分市场将在预测期内增长。复合年增长率最高。当患者使用新鲜冰冻血浆而不是晶体或胶体进行復苏时，他们发生稀释性凝血病的可能性较小。新鲜冷冻血浆可用于治疗几乎所有类型的罕见凝血因子缺乏症。因此，预计新鲜冷冻血浆领域在预测期内将在市场上获得吸引力。

为了更了解罕见血友病因子产业的市场实施情况，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）），亚太地区根据全球分布（中国、日本、印度、亚太地区其他地区）和世界其他国家进行分析。 2022年罕见血友病因子市场由北美主导。尖端和创新产品的可用性、人们对健康问题的认识不断提高、该地区不断增长的老年人口正在推动对治疗的需求，以及对罕见出血性疾病药物研发的投资增加。有几个因素正在推动该地区的市场，包括：例如，2020 年，美国再生元製药公司 (Regeneron Pharmaceuticals) 与 Intellia 合作，共同开发一种治疗罕见遗传性血液疾病（血液无法正常凝固）的潜在疗法。按地区划分，北美在 2022 年罕见血友病因子市场中占据主导地位。

Rare bleeding disorders (RBDs) are autosomal recessive diseases including the inherited deficiencies of coagulation factors like fibrinogen, factor (F) II, III, FV, FVII, FX, FXI, FXIII, and others. These disorders are mainly caused by mutations or changes to the gene. The market is primarily driven by the increasing prevalence of rare blood disorders, such as hemophilia. These conditions are often inherited from affected parents and can result in symptoms such as uncontrolled bleeding episodes. As the global population ages, the incidence of rare blood disorders is expected to rise, thus fueling the demand for rare hemophilia factors therapeutics. Additionally, pharmaceutical advancements in the drugs have improved the safety and efficacy of rare hemophilia factors therapeutics, further driving market growth. Separate studies have found that aging patients encounter problems typical of old age compounded by hemophilia, which can cause bleeding in joints among other problems. Obesity is also a concern for people with hemophilia as they age something that can worsen joint bleeds and cause mobility issues.

The Rare Hemophilia Factors Market is expected to grow at a strong CAGR of 5.2% during the forecast period owing to the rising geriatric population. Rare bleeding disorders encompass a group of inherited blood clotting disorders that are less common than hemophilia. These disorders are often acquired by people of old age. According to the U.S. Census Bureau, the global population aged 65 and older is projected to reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide.

Based on type, the market is categorized into Factor I, Factor II, Factor VII, Factor X, Factor XIII, and others. The Factor VII segment held the majority share of the market in 2022 because of a high incidence of this deficiency. According to the National Bleeding Disorders Foundation, Factor VII deficiency has an incidence of 1 in 300,000-500,000 people or 2.5 cases per million. Factor VII is one of the most important coagulation proteases in the clotting cascade and is largely responsible for starting the proteolytic events that ultimately result in thrombin generation, fibrin deposition, and platelet activation. The deficiency is usually inherited in an autosomal recessive manner equally among men and women, both parents must carry the gene to carry it to their children. Hence, the Factor VII segment held a significant share of the market in the year 2022.

Based on treatment, the market is segmented into factor concentrates, fresh frozen plasma, cryoprecipitate, and others. The fresh frozen plasma segment is expected to grow with the highest CAGR during the forecast period owing to rising demand for medicines, the need for safe options for medicines, strategic collaborations and collaborations, and innovative product launches that have further increased the demand for intelligent products. When patients are revived with fresh frozen plasma rather than crystalloid or colloid, they are less likely to develop a dilutional coagulopathy. Fresh frozen plasma can be used as a treatment method for nearly all rare blood clotting factor deficiency types. Thus, the fresh frozen plasma segment is expected to gain prominence in the market in the forecast period.

For a better understanding of the market adoption of the rare hemophilia factors industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of rare hemophilia factors in 2022. Several factors such as the availability of cutting-edge and innovative products, growing awareness of health concerns, the rising geriatric population in the region are increasing the demand for therapeutics, and loaded investment in rare bleeding disorder drug discovery are driving the market in the region. For instance, in 2020, U.S.-based Regeneron Pharmaceuticals partnered with Intellia to co-develop potential treatments for rare blood disorders, which are genetic in fashion that prevent blood from clotting properly. North America dominated the rare hemophilia factors market among regions in the year 2022.

Some of the major players operating in the market include: Novo Nordisk A/S; Bayer AG; CSL; Takeda Pharmaceutical Company Limited; Bio Products Laboratory Ltd.; Octapharma AG; F. Hoffmann-La Roche Ltd; KM Biologics; GC Biopharma Corp.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Rare Hemophilia Factors Market
2.2. Research Methodology of the Rare Hemophilia Factors Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE RARE HEMOPHILIA FACTORS MARKET

6 RARE HEMOPHILIA FACTORS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

7.1. Factor I
7.2. Factor II
7.3. Factor VII
7.4. Factor X
7.5. Factor XIII
7.6. Others

8 MARKET INSIGHTS BY TREATMENT

8.1. Factor Concentrates
8.2. Fresh Frozen Plasma
8.3. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World